CRISPR Therapeutics AG (NASDAQ:CRSP) Stake Boosted by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. boosted its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 14.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 39,189 shares of the company's stock after buying an additional 4,914 shares during the period. Cambridge Investment Research Advisors Inc.'s holdings in CRISPR Therapeutics were worth $1,334,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the company. Intellectus Partners LLC increased its position in CRISPR Therapeutics by 3.6% during the fourth quarter. Intellectus Partners LLC now owns 7,131 shares of the company's stock worth $281,000 after buying an additional 250 shares during the period. Farrow Financial Inc. increased its holdings in shares of CRISPR Therapeutics by 1.4% in the fourth quarter. Farrow Financial Inc. now owns 20,097 shares of the company's stock valued at $777,000 after purchasing an additional 270 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of CRISPR Therapeutics by 7.6% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 5,252 shares of the company's stock valued at $215,000 after purchasing an additional 372 shares during the period. Horizon Kinetics Asset Management LLC increased its holdings in shares of CRISPR Therapeutics by 4.3% in the fourth quarter. Horizon Kinetics Asset Management LLC now owns 10,682 shares of the company's stock valued at $420,000 after purchasing an additional 443 shares during the period. Finally, Capital Group Investment Management PTE. LTD. increased its holdings in shares of CRISPR Therapeutics by 2.1% in the fourth quarter. Capital Group Investment Management PTE. LTD. now owns 27,698 shares of the company's stock valued at $1,090,000 after purchasing an additional 582 shares during the period. Institutional investors and hedge funds own 69.20% of the company's stock.

CRISPR Therapeutics Stock Down 1.9%

Shares of CRSP stock traded down $0.98 during trading hours on Monday, hitting $51.19. 2,179,375 shares of the company were exchanged, compared to its average volume of 1,898,213. The firm has a market cap of $4.42 billion, a PE ratio of -11.33 and a beta of 1.82. CRISPR Therapeutics AG has a 1 year low of $30.04 and a 1 year high of $63.68. The firm has a fifty day moving average of $40.95 and a 200 day moving average of $40.81.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 20.08% and a negative net margin of 1,023.64%. The company's quarterly revenue was up 71.6% on a year-over-year basis. During the same quarter last year, the company posted ($1.43) EPS. Analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

CRSP has been the topic of several research analyst reports. Barclays decreased their target price on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a research report on Friday, May 9th. JMP Securities reiterated a "market outperform" rating and issued a $86.00 price objective on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Wall Street Zen upgraded shares of CRISPR Therapeutics to a "sell" rating in a research report on Friday, May 16th. Piper Sandler reiterated an "overweight" rating and issued a $105.00 price objective on shares of CRISPR Therapeutics in a research report on Friday, June 27th. Finally, The Goldman Sachs Group decreased their price objective on shares of CRISPR Therapeutics from $53.00 to $47.00 and set a "neutral" rating on the stock in a research report on Thursday, May 8th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and ten have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $71.75.

Insider Transactions at CRISPR Therapeutics

In other news, insider Naimish Patel sold 3,932 shares of the firm's stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $35.94, for a total transaction of $141,316.08. Following the completion of the sale, the insider owned 6,068 shares of the company's stock, valued at approximately $218,083.92. This trade represents a 39.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.10% of the stock is owned by company insiders.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.